... QUEBEC CITY April 15 / AEterna Zentaris In... We are very proud to have reached this important milestone. The Phase...This first efficacy study titled Cetrorelix pamoate intermittent IM...About the Phase 3 Program with Cetrorelix in BPH ...

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
(NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on
endocrine therapy and oncology, today reported the completion of patient
recruitment for the Company's first efficacy trial of its Phase 3 program
in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the
prostate, with its flagship product candidate, cetrorelix. The study
involves approximately 600 patients primarily in the United States and
Canada, with additional sites in Europe.

"We are very proud to have reached this important milestone. The Phase
3 program in BPH with cetrorelix is on track and we expect to provide
results in the third quarter of 2009 as stated previously," commented Paul
Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna
Zentaris.

The first multi-center efficacy study commenced first patient
randomization in April 2007 and completion of patient recruitment was
announced today. It is currently being conducted primarily in the United
States and Canada, with additional sites in Europe and involves
approximately 600 patients under the supervision of lead investigator,
Herbert Lepor, MD, Professor at NY University School of Medicine, New York.
Patients enter a 4-week run-in no-treatment observation period to confirm
severity and stability of voiding symptoms based on the International
Prostate Symptom Score (IPSS). Patients are then randomly allocated to
cetrorelix or placebo in a double-blind fashion. Patients are administered
cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are
followed up to Week 52. Then, in an open-label extension, patients will
receive cetrorelix by IM injection at Week 52, 54, 78 and 80, and will be
followed up to Week 90.

The second multi-center Phase 3 efficacy study for which first-patient
dosing was announced March 26, 2008, will enroll approximately 400 patients
in Europe. Patients in this randomized placebo-controlled study with
open-label extension will receive cetrorelix according to similar dosing
regimens used in the first study.

The primary endpoint for both efficacy studies is absolute change in
IPSS between baseline and Week 52. Other efficacy endpoints include
additional measures of BPH-symptom progression and the need for BPH-related
surgery. Safety endpoints include changes in sexual function. Other
important endpoints include plasma changes in levels of testosterone and
assessment of other adverse events.

The third study in the Phase 3 program, expected to commence shortly,
is an open-label, single-armed, multi-center safety study involving
approximately 500 patients in both North America and Europe.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases
of aging men - affecting more than 20 million men in the United States -
but its etiology is far from being completely understood. Data from ongoing
research suggest BPH and lower urinary tract symptoms (LUTS) are more
complex conditions than once thought. While previous research on BPH
etiology tended to focus on testosterone and other hormones, more recent
research suggests other factors - including inflammation, various growth
factors, and adrenoreceptors - actually may play a greater role in the
development of BPH and LUTS.

BPH is associated with LUTS, including: frequent urination, a sudden,
uncontrollable urge to urinate, waking at night to urinate (nocturia),
difficulty starting a urine stream (hesitancy and straining), decreased
strength of the urine stream (weak flow), feeling that the bladder is not
completely empty, an urge to urinate again soon after urinating and pain
during urination (dysuria). Currently available therapies may improve
symptoms to some degree, but often come with sexual and other side effects.

About Cetrorelix

Cetrorelix pamoate is an investigational agent that has shown in Phase
2 studies to provide fast and long lasting relief of BPH symptoms and was
well tolerated, with a low incidence of sexual side effects. Cetrorelix is
part of AEterna Zentaris' LHRH antagonist therapeutic approach. This
peptide-based active substance was developed by the Company in cooperation
with Nobel Prize winner Prof. Andrew Schally, currently of the U.S.
Veterans Administration in Miami.

In addition to the Phase 3 program in BPH, cetrorelix pamoate is also
being studied in a Phase 2b program in this same indication in Japan,
sponsored by the Company's partner, Shionogi.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the
first LHRH antagonist approved for therapeutic use as part of in vitro
fertilization programs (controlled ovulation stimulation/assisted
reproductive technologies) in Europe, the U.S. and Japan. It was launched
on the market through Serono (now Merck Serono) in the U.S., Europe and in
several other countries, as well as in Japan through Shionogi.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology, with proven expertise in drug discovery,
development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and
resources to pursue R&D projects, the successful and timely completion of
clinical studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company does
not undertake to update these forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments except if we are requested
by a governmental authority or applicable law.

(Date:12/7/2016)... Mich. , Dec. 7, 2016 Neogen ... has named Dr. Dan Kephart as its ... company. Kephart will assume his responsibilities at Neogen effective ... and development director for the agribusiness unit of Thermo ... safety development at Life Technologies. His extensive industry experience ...

(Date:12/7/2016)... SAN DIEGO , Dec. 7, 2016 Biocom, the ... community, issued the statement below following passage of 21 st ... the House on November 30 by a 392-26 vote and ... This statement may be attributed to Joe Panetta , ... historic legislation that will give hope to millions of patients ...

(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...

(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...

(Date:11/22/2016)... Nov. 22, 2016 MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...